Venus Medtech (Hangzhou) (SZSC:2500) - Prezzo delle azioni, notizie e analisi

2500 Panoramica delle azioni

Engages in the research, development, clinical development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally.

Informazioni sull'azienda

2500 analisi fondamentale
Punteggio fiocco di neve
Valutazione	3/6
Crescita futura	2/6
Prestazioni passate	0/6
Salute finanziaria	4/6
Dividendi	0/6

Premi

Negoziato a 23.4% al di sotto della nostra stima del suo valore equo

Si prevede che i ricavi cresceranno 31.93% all'anno

Analisi del rischio

Le azioni sono altamente illiquide

Attualmente non redditizio e non si prevede che diventerà redditizio nei prossimi 3 anni

Venus Medtech (Hangzhou) Inc. Concorrenti

Acotec Scientific Holdings

SEHK:6669

HK$2.4b

Sisram Medical

SEHK:1696

HK$1.7b

MicroPort CardioFlow Medtech

SEHK:2160

HK$1.7b

Modern Dental Group

SEHK:3600

HK$3.6b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Venus Medtech (Hangzhou)
Prezzi storici delle azioni
Prezzo attuale dell'azione	HK$5.62
Massimo di 52 settimane	HK$14.94
Minimo di 52 settimane	HK$3.74
Beta	0.55
1Variazione di 1 mese	0%
Variazione a 3 mesi	-0.71%
Variazione di 1 anno	-61.61%
3Variazione a 3 anni	-92.66%
Variazione a 5 anni	n/a
Variazione dall'IPO	-92.89%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	2500	HK Medical Equipment	HK Mercato
7D	0%	-2.6%	-1.0%
1Y	-61.6%	-34.1%	15.0%

Ritorno vs Industria: 2500 ha avuto una performance inferiore rispetto al Hong Kong Medical Equipment che ha registrato un rendimento -34.1 % nell'ultimo anno.

Rendimento vs Mercato: 2500 ha avuto una performance inferiore al mercato Hong Kong che ha registrato un rendimento 15 % nell'ultimo anno.

Volatilità dei prezzi

Is 2500's price volatile compared to industry and market?
2500 volatility
2500 Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	9.8%
Market Average Movement	8.9%
10% most volatile stocks in HK Market	18.8%
10% least volatile stocks in HK Market	4.3%

Prezzo delle azioni stabile: 2500 non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di 2500 nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2009	1,006	Lin Haosheng Lim	www.venusmedtech.com

Venus Medtech (Hangzhou) Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Venus Medtech (Hangzhou) con la sua capitalizzazione di mercato?
2500 statistiche fondamentali
Capitalizzazione di mercato	HK$2.46b
Guadagni(TTM)	-HK$1.31b
Ricavi(TTM)	HK$491.35m

5.0x

Rapporto P/S

-1.9x

Rapporto P/E

2500 è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
2500 Conto economico (TTM)
Ricavi	CN¥452.11m
Costo del fatturato	CN¥101.03m
Profitto lordo	CN¥351.07m
Altre spese	CN¥1.56b
Guadagni	-CN¥1.21b

Ultimi guadagni dichiarati

Jun 30, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	-2.76
Margine lordo	77.65%
Margine di profitto netto	-267.18%
Rapporto debito/patrimonio netto	23.4%

Come si è comportato 2500 nel lungo periodo?

Vedi performance storica e confronto

2500 Panoramica delle azioni

Premi

Analisi del rischio

Venus Medtech (Hangzhou) Inc. Concorrenti

SEHK:6669

HK$2.4b

SEHK:1696

HK$1.7b

SEHK:2160

HK$1.7b

SEHK:3600

HK$3.6b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Venus Medtech (Hangzhou) Inc. Appoints Bing Zhu as the Chief Financial Officer

Venus Medtech Venus-Vitae Completes First Two Implantations in SMART-ALIGN Pivotal Clinical Study

Venus Medtech (Hangzhou) Inc. Announces Supervisor and Supervisory Committee Changes

Venus Medtech (Hangzhou) Inc. to Report First Half, 2024 Results on Aug 30, 2024

Venus Medtech Venusp-Valve Completes First Implantation in Ide Pivotal Clinical Study in U.S

Venus Medtech (Hangzhou) Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

Recent updates

Venus Medtech (Hangzhou) Inc. Appoints Bing Zhu as the Chief Financial Officer

Venus Medtech Venus-Vitae Completes First Two Implantations in SMART-ALIGN Pivotal Clinical Study

Venus Medtech (Hangzhou) Inc. Announces Supervisor and Supervisory Committee Changes

Venus Medtech (Hangzhou) Inc. to Report First Half, 2024 Results on Aug 30, 2024

Venus Medtech Venusp-Valve Completes First Implantation in Ide Pivotal Clinical Study in U.S

Venus Medtech (Hangzhou) Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

Venus Medtech (Hangzhou) Inc. Announces That Wan Yee Joseph Lau, an Independent Non-Executive Director, the Chairman of the Nomination Committee and A Member of Each of the Remuneration and Assessment Committee and the Audit Committee of the Board, Passed Away

Venus Medtech (Hangzhou) Inc. Appoints Fei Wang as the Chief Financial Officer

Venus Medtech (Hangzhou) Inc. Approves Mr. Liqiao Ma as an Executive Director

New minor risk - Share price stability

Venus Medtech (Hangzhou) Inc. Announces Executive Changes

No longer forecast to breakeven

Venus Medtech (Hangzhou) Inc. Announces Appointment of Mr. Lim Housen (Lin Haosheng) as Joint Chief Executive Officer with Effect from September 22, 2023

No longer forecast to breakeven

New minor risk - Profitability

Venus Medtech (Hangzhou) Inc. to Report First Half, 2023 Results on Aug 31, 2023

New minor risk - Share price stability

Founder recently bought HK$1.9m worth of stock

Venus Medtech (Hangzhou) Inc., Annual General Meeting, Jun 30, 2023

Venus Medtech (Hangzhou) Inc. Announces Resignation of Haiyue Ma as Joint Company Secretary

Forecast to breakeven in 2025

Less than half of directors are independent

Venus Medtech (Hangzhou) Inc. Announces Board Changes

Insider recently sold HK$5.7m worth of stock

Venus Medtech (Hangzhou) Inc. Announces Resignation of Lim Hou-Sen as an Executive Director and Nisa Bernice Wing-Yu Leung as Non-Executive Director and Vice Chairwoman

Less than half of directors are independent

First half 2022 earnings released: CN¥0.46 loss per share (vs CN¥0.26 loss in 1H 2021)

Venus Medtech (Hangzhou) Inc. Announces Change of Employee Representative Supervisor and Chairperson of the Supervisory Committee

First half 2022 earnings released: EPS: CN¥0 (vs CN¥0.26 loss in 1H 2021)

Venus Medtech (Hangzhou) Inc. Announces Change of Employee Representative Supervisor and Chairperson of the Supervisory Committee

Venus Medtech (Hangzhou) Inc. to Report First Half, 2022 Results on Aug 31, 2022

China's National Medical Products Administration Approves Venusp-Valve, Venus Medtech's In-House Developed Innovative Transcatheter Pulmonic Valve Replacement System

Venus Medtech (Hangzhou) Inc. Announces First American Patient Treated with VenusP-Valve Under Compassionate Use

Less than half of directors are independent

Venus Medtech (Hangzhou) Inc. Announces Expandable Bioprosthetic Dry Tissue Valve Venus-Neo Completed First Clinical Application

No longer forecast to breakeven

Forecast breakeven date pushed back to 2023

Venus Medtech (Hangzhou) Inc., Annual General Meeting, May 30, 2022

Venus Medtech (Hangzhou) Inc. to Report Fiscal Year 2021 Results on Mar 31, 2022

Venus Medtech (Hangzhou) Inc. Appoints Amir Gross as Head of Venus Global Heart Valve Innovation Center

Venus Medtech (Hangzhou) Inc. Announces Completion of Global First Clinical Application of Venus-Powerx

Venus Medtech (Hangzhou) Inc. Announces Venus Vitae, Balloon-Expandable Dry Tissue Tavr System Successfully Completed the First Two Implantations in the Fim Clinical Trial

Venus Medtech (Hangzhou) Inc. (SEHK:2500) commences an Equity Buyback Plan for 43,170,744 shares, representing 9.79% of its issued share capital, under the authorization approved on May 21, 2021.

Forecast to breakeven in 2022

Forecast to breakeven in 2022

First half 2021 earnings released: CN¥0.26 loss per share (vs CN¥0.11 loss in 1H 2020)

Forecast to breakeven in 2022

GM & Executive Director recently bought HK$35m worth of stock

GM & Executive Director recently bought HK$6.0m worth of stock

GM & Executive Director recently bought HK$30m worth of stock

Full year 2020 earnings released: CN¥0.45 loss per share (vs CN¥1.22 loss in FY 2019)

Full year 2020 earnings released: CN¥0.45 loss per share (vs CN¥1.22 loss in FY 2019)

Venus Medtech (Hangzhou) Inc. to Report Fiscal Year 2020 Results on Mar 31, 2021

Venus Medtech (Hangzhou) Inc. has completed a Follow-on Equity Offering in the amount of HKD 1.444843 billion.

GM & Executive Director recently sold HK$304m worth of stock

Venus Medtech (Hangzhou) Inc. Announces its CEP Device, TriGUARD3, Completes its First Clinical Application in the PRC

Venus Medtech (Hangzhou) Inc. Announces Change of Joint Company Secretary

COO, CTO & Executive Director recently sold HK$280m worth of stock

COO, CTO & Executive Director recently sold HK$193m worth of stock